Events & Academic Programs
Intra-Departmental Academic Programs
| Sl No | Date | Topic | Speaker |
|---|---|---|---|
| 01 | 03/03/2024 | Updates in management of Acute Leukemias Updates in management of Metastatic Breast Cancer Updates in management of colorectal Malignancies Updates in management of NSCLC | Dr. Linu Abraham Jacob Dr. Lokesh K N Dr. Rudresha A H Dr. Smitha C Saldanha |
| 02 | 07/03/2024 | Evolving trends in the management of her2 positive Metastatic Breast Cancer | Dr. Lokesh K N |
| 03 | 14/03/2024 | Polatuzumab vedotin in previously untreated Diffuse large B cell Lymphoma (DLBCL) | Dr. Suresh Babu M C |
| 04 | 09/05/2024 | Systemic Therapy in HCC:Myths and facts | Dr. Amit Singal |
| 05 | 23/05/2024 | Management of NSCLC- An Indian Innovation | Dr. Suresh Babu M C |
| 06 | 30/05/2024 | Role of Romiplastim in chemotherapy induced Thrombocytopenia & ITP. Solving the taxing problem of taxanes with newer formulations | Dr. Smitha C Saldanha Dr. K N Lokesh |
| 07 | 06/06/2024 | Gilteritinib in relapsed/refractory AML. | Dr. Linu Abraham Jacob |
| 08 | 24/6/2024 | (a) Unmet needs in high risk HR +ve HER2 –ve Breast Cancer (EBC) | Dr. Harmut Kristeleit |
| 09 | 4/9/2024 | (a)Trastuzumab beyond Breast Cancer (b)Bevacizumab in combination with Immunotherapy | Dr. Rudresh A.H Dr. Rajeev L.K |
| 10 | 11/7/2024 | (a) Relugolix in advance Prostate Cancer | Dr. LNV Abraham Jacob |
| 11 | 22/8/2024 | Breast Cancer update: Pertuzumab | Dr. Lokesh KN |
| 12 | 6/3/2027 | (a) Optimizing prostate cancer therapy: Benefits of GnRH antagonists (b) Optimizing use of TDM1 in Indian patients: Balancing efficacy and safety | Dr. L.K. Rajeev Dr. Lokesh KN |
| 13 | 20/3/2025 | Sequencing strategy for maximizing use of HR +ve, HER2 +ve Breast Cancer | Dr. Lokesh KN |
| 14 | 7/4/2025 | optimizing outcome in 1c ineligible AML patient | Dr. Yakir Moshe |
| 15 | 3/7/2025 | Recent updates in CML | Dr. Lokesh KN |
| 16 | 16/8/2025 | Expanding horizon in metastatic EGFRm NSCLC with combination therapy | Dr. Suresh Babu |
| 17 | 22/8/2025 | Evolving 1st line CML landscape | Dr. Suresh Babu |
| 18 | 25/9/2025 | ALK strategies in the management of ALK+ve NSCLC with ALUNBRIG | Dr. Lokesh KN |
| 19 | 27/01/26 | Response monitoring and role of FLT3 MRD in R/R AML, sequencing of therapies in AML, post transplant maintenance, mutation resistant to FLT3 inhibitors | Dr Mark James |
| 20 | 29/01/26 | optimizing myelofibrosis treatment - Early treatment with Ruxolitinib & the challenges of myelofibrosis | Dr. Lokesh KN |